The company may issue, in one or more offerings, up to $250M in aggregate principal amount of its common stock, preferred stock, debt securities, warrants and/or units, at prices and on terms that it will determine at the time of the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
- Eledon Pharmaceuticals completes enrollment for Phase 2 BESTOW trial
- Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
- Eledon Pharmaceuticals provides Q2 corporate update
- Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results